Dr. Michael Rachshtut, MD

Dr. Rachshtut practices at Cooper University Hospital in Camden, New Jersey, part of Cooper University Health Care.

Dr. Rachshtut's NPI, 1912153792, was assigned on August 13, 2008. Dr. Rachshtut holds New Jersey license 25MA08080500.

Dr. Rachshtut's primary practice is Cooper University Hospital, at 1 Cooper Plaza, Camden, NJ 08103 in Camden County. The practice phone is (856) 342-2000.

Dr. Rachshtut's primary practice is Cooper University Hospital in Camden, New Jersey, part of Cooper University Health Care. Dr. Rachshtut is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Cooper University Physicians. Dmand AI also links Dr. Rachshtut to 1 more hospital, 3 medical groups, 2 home health agencies and 1 skilled nursing facility, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rachshtut practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Rachshtut's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Rachshtut's licenses on file in 2 states: New Jersey and Pennsylvania.

CMS data shows 1,121 Medicare services from Dr. Rachshtut across 7 procedure codes in 2024, for 469 Medicare patients. Medicare paid $109,326 for them.

CMS counts 469 Medicare patients who saw Dr. Rachshtut in 2024. The largest group is 65 to 74, with 179 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 42% are also on Medicaid. Their average risk score is 2.03, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rachshtut's median patient age at 67, with 67% women.

In 2024, Dr. Rachshtut wrote 1,806 Medicare Part D claims for 247 patients. 52% of them were for generic drugs. CMS names the drug for 1,517 of them, across 40 drugs with 11 or more claims each, at $3,870,452 in total drug cost. In 2023, CMS named 1,592 claims across 47 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 23 out of 100 for Dr. Rachshtut for performance year 2024, reported individually. Dr. Rachshtut accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 2 papers to Dr. Rachshtut in 2015. Dr. Rachshtut's most frequent co-authors are Vivek R. Mehta, MD and Sufana Shikdar, MD, MPH.

CMS Open Payments shows 671 general payments to Dr. Rachshtut from 34 drug and device companies from 2016 to 2024. Speaker and faculty fees make up the largest share, 87% of the total. Pfizer Inc. paid the most, $152,809.